NGM Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Cash & Equivalents	61.27	77.41	153.29	148.52	247.47	59.17	27.84
Short-Term Investments	88.37	198.04	214.46	148.14	98.91	149.71	148.09
Cash & Cash Equivalents	149.64	275.45	367.75	296.66	346.39	208.88	175.93
Cash Growth	-45.67%	-25.10%	23.97%	-14.36%	65.83%	18.73%	-
Receivables	0.06	7.58	4.95	0.33	5.21	3.67	0
Other Current Assets	6.75	5.83	6.58	11.44	3.66	2.01	-0.4
Total Current Assets	156.44	288.86	379.28	308.43	355.25	214.56	175.53
Property, Plant & Equipment	7.03	10.59	14.12	14.53	19.48	23.89	24.87
Long-Term Investments	0	0	0	0	0	0	45.15
Other Long-Term Assets	5.39	7.95	8.99	6.09	5.68	7.64	3.39
Total Long-Term Assets	12.42	18.54	23.11	20.62	25.16	31.53	73.41
Total Assets	168.87	307.4	402.39	329.04	380.4	246.09	248.94
Accounts Payable	2.98	8.45	5.25	9.66	9.03	5.78	1.89
Deferred Revenue	0	0.37	17.77	0	4.87	22.97	44.1
Current Debt	0	5.39	5.08	0	0	0	0
Other Current Liabilities	17.1	33.64	33.26	32.92	25.82	12.74	-9.1
Total Current Liabilities	20.08	47.84	61.36	42.58	39.72	41.49	36.89
Long-Term Debt	0	0	5.39	0	0	0	0
Other Long-Term Liabilities	0.15	0	0	6.42	9.97	17.92	38.15
Total Long-Term Liabilities	0.15	0	5.39	6.42	9.97	17.92	38.15
Total Liabilities	20.23	47.84	66.74	49	49.68	59.41	75.05
Total Debt	0	5.39	10.46	0	0	0	0
Debt Growth	-	-48.53%	-	-	-	-	-
Retained Earnings	-724.01	-581.63	-418.97	-298.63	-196.14	-147.19	-146.7
Comprehensive Income	0.02	-0.3	-0.13	0	0.03	-0.27	-0.43
Shareholders' Equity	148.64	259.56	335.65	280.04	330.72	-108.2	-120.98
Net Cash / Debt	149.64	270.06	357.29	296.66	346.39	208.88	175.93
Net Cash / Debt Growth	-44.59%	-24.41%	20.44%	-14.36%	65.83%	18.73%	-
Net Cash Per Share	1.81	3.38	4.64	4.33	6.89	32.72	29.51
Working Capital	136.36	241.02	317.93	265.84	315.53	173.07	138.64
Book Value Per Share	1.80	3.25	4.35	4.09	6.58	-16.95	-20.29

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).